Administration of the asthma medication montelukast more than 30 minutes before infusion of daratumumab can drastically reduce infusion-related reactions in patients with multiple myeloma.
In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.
To sign up for our newsletter or print publications, please enter your contact information below.